Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia.

Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, Wallace DC.

J Alzheimers Dis. 2010;20 Suppl 2:S293-310. doi: 10.3233/JAD-2010-100351.

2.

Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication.

Coskun PE, Beal MF, Wallace DC.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10726-31. Epub 2004 Jul 9.

3.

A mitochondrial etiology of Alzheimer and Parkinson disease.

Coskun P, Wyrembak J, Schriner SE, Chen HW, Marciniack C, Laferla F, Wallace DC.

Biochim Biophys Acta. 2012 May;1820(5):553-64. doi: 10.1016/j.bbagen.2011.08.008. Epub 2011 Aug 16. Review.

4.

Mitochondrial DNA copy numbers in pyramidal neurons are decreased and mitochondrial biogenesis transcriptome signaling is disrupted in Alzheimer's disease hippocampi.

Rice AC, Keeney PM, Algarzae NK, Ladd AC, Thomas RR, Bennett JP Jr.

J Alzheimers Dis. 2014;40(2):319-30. doi: 10.3233/JAD-131715.

PMID:
24448779
5.

Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome.

Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA.

Neuron. 2002 Feb 28;33(5):677-88.

6.

Genetic basis of Alzheimer's dementia: role of mtDNA mutations.

Grazina M, Pratas J, Silva F, Oliveira S, Santana I, Oliveira C.

Genes Brain Behav. 2006;5 Suppl 2:92-107. Review.

7.

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ.

Neurobiol Dis. 1996 Feb;3(1):16-32.

PMID:
9173910
8.

Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Martin SB, Dowling AL, Lianekhammy J, Lott IT, Doran E, Murphy MP, Beckett TL, Schmitt FA, Head E.

J Alzheimers Dis. 2014;42(3):767-75. doi: 10.3233/JAD-140795.

9.

Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.

Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E.

Neurobiol Aging. 2015 Sep;36(9):2468-74. doi: 10.1016/j.neurobiolaging.2015.05.016. Epub 2015 May 30.

10.

Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome.

Naudé PJ, Dekker AD, Coppus AM, Vermeiren Y, Eisel UL, van Duijn CM, Van Dam D, De Deyn PP.

J Alzheimers Dis. 2015;45(3):733-43. doi: 10.3233/JAD-142514.

PMID:
25613101
11.

Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W.

Neurology. 2010 Nov 2;75(18):1639-44. doi: 10.1212/WNL.0b013e3181fb448b.

12.

Atypical aging in Down syndrome.

Zigman WB.

Dev Disabil Res Rev. 2013;18(1):51-67. doi: 10.1002/ddrr.1128. Review.

PMID:
23949829
13.

Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Mehta PD, Capone G, Jewell A, Freedland RL.

J Neurol Sci. 2007 Mar 15;254(1-2):22-7. Epub 2007 Feb 2.

PMID:
17275850
14.

Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease.

Coskun P, Helguera P, Nemati Z, Bohannan RC, Thomas J, Samuel SE, Argueta J, Doran E, Wallace DC, Lott IT, Busciglio J.

J Alzheimers Dis. 2017;55(2):737-748.

PMID:
27802222
15.
16.
17.

Heteroplasmy of mitochondrial D310 mononucleotide repeat region in the blood of patients with Alzheimer's disease.

Wang PN, Lee HC, Wang CH, Ping YH, Liu TY, Chi CW, Lin KN, Liu HC.

J Alzheimers Dis. 2009;18(2):345-53. doi: 10.3233/JAD-2009-1156.

PMID:
19584455
18.

Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease.

Onyango I, Khan S, Miller B, Swerdlow R, Trimmer P, Bennett P Jr.

J Alzheimers Dis. 2006 Jul;9(2):183-93. Review.

PMID:
16873965
19.

Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, Lott IT.

J Alzheimers Dis. 2011;23(3):399-409. doi: 10.3233/JAD-2010-101335.

20.

Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease.

Kukreja L, Kujoth GC, Prolla TA, Van Leuven F, Vassar R.

Mol Neurodegener. 2014 May 2;9:16. doi: 10.1186/1750-1326-9-16.

Supplemental Content

Support Center